Lineage Cell Therapeutics (LCTX) Net Cash Flow (2010 - 2026)

Lineage Cell Therapeutics has reported Net Cash Flow for 17 years, with the latest figure at -$4.8 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 334.98% year-over-year to -$4.8 million; the trailing twelve-month figure through Mar 2026 stood at -$12.3 million (down 385.55% YoY), and the FY2025 full-year result was -$5.4 million, down 151.89% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$4.8 million, down from $167000.0 in the prior quarter.
• The five-year high for Net Cash Flow was $22.4 million in Q1 2022, with the low at -$45.4 million in Q3 2022.
• Historically, Net Cash Flow has averaged -$1.1 million across 5 years, with a median of -$1.8 million in 2025.
• Annual changes were most pronounced in 2022 — Net Cash Flow tumbled 3695.32% — and 2024, when it surged 385.8%.
• Lineage Cell Therapeutics' Net Cash Flow stood at -$13.3 million in 2022, then soared by 127.93% to $3.7 million in 2023, then surged by 385.8% to $18.0 million in 2024, then slumped by 99.07% to $167000.0 in 2025, then sank by 3000.0% to -$4.8 million in 2026.
• The last three Net Cash Flow figures came in at -$4.8 million (Q1 2026), $167000.0 (Q4 2025), and -$1.8 million (Q3 2025), per Business Quant data.